KR20250123934A - 올리고뉴클레오티드 제조 기술 - Google Patents

올리고뉴클레오티드 제조 기술

Info

Publication number
KR20250123934A
KR20250123934A KR1020257025660A KR20257025660A KR20250123934A KR 20250123934 A KR20250123934 A KR 20250123934A KR 1020257025660 A KR1020257025660 A KR 1020257025660A KR 20257025660 A KR20257025660 A KR 20257025660A KR 20250123934 A KR20250123934 A KR 20250123934A
Authority
KR
South Korea
Prior art keywords
oligonucleotides
capping
oligonucleotide
modification
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257025660A
Other languages
English (en)
Korean (ko)
Inventor
키이스 앤드류 보우만
찬드라 바르기스
데이비드 찰스 도넬 버틀러
파차무투 칸다사미
모하메드 로우숀 알람
마모루 시미즈
스테파니 미셸 스탠들리
빈센트 아두다
고팔 레디 봄미네니
스네흘라타 트리파시
일리아 코르보우크
Original Assignee
웨이브 라이프 사이언시스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 웨이브 라이프 사이언시스 리미티드 filed Critical 웨이브 라이프 사이언시스 리미티드
Publication of KR20250123934A publication Critical patent/KR20250123934A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
KR1020257025660A 2017-09-18 2018-09-17 올리고뉴클레오티드 제조 기술 Pending KR20250123934A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762560169P 2017-09-18 2017-09-18
US62/560,169 2017-09-18
KR1020207010806A KR20200052369A (ko) 2017-09-18 2018-09-17 올리고뉴클레오티드 제조 기술
PCT/US2018/051398 WO2019055951A1 (en) 2017-09-18 2018-09-17 OLIGONUCLEOTIDE PREPARATION TECHNOLOGIES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207010806A Division KR20200052369A (ko) 2017-09-18 2018-09-17 올리고뉴클레오티드 제조 기술

Publications (1)

Publication Number Publication Date
KR20250123934A true KR20250123934A (ko) 2025-08-18

Family

ID=65723422

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257025660A Pending KR20250123934A (ko) 2017-09-18 2018-09-17 올리고뉴클레오티드 제조 기술
KR1020207010806A Ceased KR20200052369A (ko) 2017-09-18 2018-09-17 올리고뉴클레오티드 제조 기술

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207010806A Ceased KR20200052369A (ko) 2017-09-18 2018-09-17 올리고뉴클레오티드 제조 기술

Country Status (9)

Country Link
US (3) US11608355B2 (cg-RX-API-DMAC10.html)
EP (1) EP3684755A4 (cg-RX-API-DMAC10.html)
JP (2) JP7472018B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250123934A (cg-RX-API-DMAC10.html)
CN (1) CN111108096A (cg-RX-API-DMAC10.html)
AU (2) AU2018333065B2 (cg-RX-API-DMAC10.html)
CA (1) CA3072110A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202000276YA (cg-RX-API-DMAC10.html)
WO (1) WO2019055951A1 (cg-RX-API-DMAC10.html)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
AU2015367378A1 (en) 2014-12-17 2017-06-15 Proqr Therapeutics Ii B.V. Targeted RNA editing
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
MA43822A (fr) 2016-03-13 2018-11-28 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
EP3452596A4 (en) 2016-05-04 2020-03-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
EP3475424A1 (en) 2016-06-22 2019-05-01 ProQR Therapeutics II B.V. Single-stranded rna-editing oligonucleotides
WO2018041973A1 (en) 2016-09-01 2018-03-08 Proqr Therapeutics Ii B.V. Chemically modified single-stranded rna-editing oligonucleotides
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
MX2022014606A (es) 2020-05-22 2023-03-08 Wave Life Sciences Ltd Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
MX2023007242A (es) * 2020-12-18 2023-06-29 Lilly Co Eli Sintetizador de oligonucleotidos de lecho fluidizado oscilante.
EP4479535A1 (en) 2022-02-14 2024-12-25 ProQR Therapeutics II B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
EP4555086A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Oligonucleotides for adar-mediated rna editing and use thereof
EP4555085A1 (en) 2022-07-15 2025-05-21 ProQR Therapeutics II B.V. Chemically modified oligonucleotides for adar-mediated rna editing
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
KR20250113455A (ko) 2022-11-24 2025-07-25 프로큐알 테라퓨틱스 Ⅱ 비.브이. 유전성 hfe-혈색소침착증의 치료를 위한 안티센스 올리고뉴클레오티드
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
JP2026510408A (ja) 2023-03-24 2026-04-02 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 神経障害の処置のためのアンチセンスオリゴヌクレオチド
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
EP4688143A1 (en) 2023-03-27 2026-02-11 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of liver disease
WO2024256620A1 (en) 2023-06-16 2024-12-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease
AU2024287308A1 (en) 2023-07-13 2025-12-18 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
EP4774393A1 (en) 2023-09-07 2026-07-15 ProQR Therapeutics II B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2025096809A1 (en) 2023-10-31 2025-05-08 Korro Bio, Inc. Oligonucleotides comprising phosphoramidate internucleotide linkages
AU2024379264A1 (en) 2023-11-16 2026-05-14 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of classic galactosemia
WO2025128799A1 (en) 2023-12-12 2025-06-19 Korro Bio, Inc. Double-stranded rna-editing oligonucleotides and uses thereof
AU2024402199A1 (en) 2023-12-20 2026-07-16 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of huntington's disease
GB202404661D0 (en) 2024-04-02 2024-05-15 Proqr Therapeutics Ii Bv Antisense oligoncleotides for the treatment of liver disease
WO2025224230A1 (en) 2024-04-25 2025-10-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of fatty liver disease
GB202410081D0 (en) 2024-07-11 2024-08-28 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of cardiovascular disease
WO2026022136A1 (en) 2024-07-23 2026-01-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of metabolic disorders
WO2026050243A1 (en) 2024-08-26 2026-03-05 Korro Bio, Inc. Galnac conjugated oligonucleotides for rna editing
WO2026060374A2 (en) 2024-09-16 2026-03-19 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2026068781A1 (en) 2024-09-30 2026-04-02 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease
WO2026093339A1 (en) 2024-10-29 2026-05-07 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of peroxisome biogenesis disorders in the zellweger spectrum (pbd-zsd)
WO2026122478A1 (en) 2024-12-02 2026-06-11 Korro Bio, Inc. Extrahepatic delivery formulations and methods
WO2026136663A1 (en) 2024-12-18 2026-06-25 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurodegenerative disease

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049656A (en) 1988-12-21 1991-09-17 Board Of Regents Of The University Of Nebraska Sequential peptide and oligonucleotide syntheses using immunoaffinity techniques
US5210264A (en) * 1992-01-10 1993-05-11 Isis Pharmaceuticals, Inc. S-(2,4-dichlorobenzyl)-β-cyanoethyl phosphorothioate diester
WO1998008809A1 (en) * 1996-08-30 1998-03-05 Hybridon, Inc. Novel sulfur transfer reagents for oligonucleotide synthesis
JP4348044B2 (ja) 2002-02-12 2009-10-21 株式会社キラルジェン 立体規則性の高いジヌクレオシドホスホロチオエートの製造法
CA2489174C (en) 2002-07-10 2013-02-05 Thomas Tuschl Rna-interference by single-stranded rna molecules
AU2003261449A1 (en) 2002-08-07 2004-02-25 Compositions for rna interference and methods of use thereof
JP2005089441A (ja) 2003-08-08 2005-04-07 Toudai Tlo Ltd 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法
JP4580870B2 (ja) 2003-09-02 2010-11-17 株式会社キラルジェン リボヌクレオチド又はリボヌクレオチド誘導体の製造方法
JP4616175B2 (ja) 2003-09-02 2011-01-19 株式会社キラルジェン 5’−ホスフィチル化モノマーおよびh−ホスホネートオリゴヌクレオチド誘導体の製造方法
JP4945129B2 (ja) 2004-01-27 2012-06-06 株式会社キラルジェン フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005085272A1 (ja) 2004-03-05 2005-09-15 Takeshi Wada ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法
WO2005092909A1 (ja) 2004-03-25 2005-10-06 Toudai Tlo, Ltd. 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法
CN101437801B (zh) 2006-03-06 2013-02-06 日本烟草产业株式会社 制备4-氧代喹啉化合物的方法
BRPI0923225A2 (pt) 2008-12-02 2016-10-04 Chiralgen Ltd metodo para sintese de acidos nucleicos modificados no atomo de fosforo
EP2451461A4 (en) 2009-07-06 2013-05-29 Ontorii Inc NOVEL NUCLEIC ACID PRODRUGS AND METHOD OF USE THEREOF
EP2479182B8 (en) 2009-09-16 2016-07-13 Wave Life Sciences Japan, Inc. Novel protecting group for synthesizing rna and derivative thereof
WO2011108682A1 (ja) 2010-03-05 2011-09-09 国立大学法人 東京大学 リボヌクレオシドホスホロチオエートの製造方法
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
EP2647644B1 (en) 2010-11-30 2020-09-09 Wave Life Sciences Japan, Inc. 2'-o-modified rna
CN107365339A (zh) 2011-07-19 2017-11-21 波涛生命科学有限公司 合成官能化核酸的方法
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
SG11201500243WA (en) 2012-07-13 2015-04-29 Shin Nippon Biomedical Lab Ltd Chiral nucleic acid adjuvant
WO2014010250A1 (en) 2012-07-13 2014-01-16 Chiralgen, Ltd. Asymmetric auxiliary group
WO2015108046A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
EP3095461A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095459A4 (en) 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having antitumor effect and antitumor agent
EP3094728B1 (en) 2014-01-16 2022-03-09 Wave Life Sciences Ltd. Chiral design
CN117965536A (zh) 2015-07-22 2024-05-03 波涛生命科学有限公司 寡核苷酸组合物及其方法
MA46427A (fr) 2015-10-09 2018-08-15 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US20190194746A1 (en) * 2016-03-09 2019-06-27 Tokyo University Of Science Foundation Nucleic acid oligomer for rna hybrid formation
MA43822A (fr) 2016-03-13 2018-11-28 Wave Life Sciences Ltd Compositions et procédés de synthèse de phosphoramidite et d'oligonucléotides
EP3452596A4 (en) 2016-05-04 2020-03-18 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS
JP2019516679A (ja) 2016-05-04 2019-06-20 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. 生物活性剤に関する方法および組成物
US11013757B2 (en) 2016-06-03 2021-05-25 Wave Life Sciences Ltd. Oligonucleotides, compositions and methods thereof
US20190264267A1 (en) 2016-07-25 2019-08-29 Wave Life Sciences Ltd. Phasing
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
US11603532B2 (en) 2017-06-02 2023-03-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CN111164091B (zh) 2017-06-02 2025-01-07 波涛生命科学有限公司 寡核苷酸组合物及其使用方法
CA3065523A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
WO2018237194A1 (en) 2017-06-21 2018-12-27 Wave Life Sciences Ltd. Compounds, compositions and methods for synthesis
WO2019002237A1 (en) 2017-06-28 2019-01-03 Roche Innovation Center Copenhagen A/S METHOD OF MULTIPLE COUPLING AND OXIDATION
AU2018316159A1 (en) 2017-08-08 2020-02-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
CN111108096A (zh) 2017-09-18 2020-05-05 波涛生命科学有限公司 寡核苷酸制备技术
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
JP2021521140A (ja) 2018-04-12 2021-08-26 ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. オリゴヌクレオチド組成物及びその使用方法
CA3098624A1 (en) 2018-05-11 2019-11-14 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2019392928A1 (en) 2018-12-06 2021-06-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP3917497A4 (en) 2019-02-01 2023-06-07 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF
AU2020241559A1 (en) 2019-03-20 2021-11-11 Wave Life Sciences Ltd. Technologies useful for oligonucleotide preparation
JPWO2020196662A1 (cg-RX-API-DMAC10.html) 2019-03-25 2020-10-01
MX2021012981A (es) 2019-04-25 2022-01-18 Wave Life Sciences Ltd Composiciones de oligonucleotido y metodos de uso de las mismas.
EP3958872A4 (en) 2019-04-25 2024-07-03 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP3965780A4 (en) 2019-05-09 2023-10-25 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
CA3154768A1 (en) 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
CA3156176A1 (en) 2019-10-06 2021-04-15 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
AU2021230473A1 (en) 2020-03-01 2022-09-22 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
MX2022014606A (es) 2020-05-22 2023-03-08 Wave Life Sciences Ltd Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas.
AU2021277407A1 (en) 2020-05-22 2022-11-17 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof
EP4200616A1 (en) 2020-08-24 2023-06-28 Wave Life Sciences Ltd. Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays
CN115989041A (zh) 2020-08-24 2023-04-18 波涛生命科学有限公司 经工程化为表达adar1的细胞和非人动物及其用途
US20230416847A1 (en) 2020-09-24 2023-12-28 Mayo Foundation For Medical Education And Research Screening platforms
JP2023548584A (ja) 2020-11-08 2023-11-17 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその方法
CN116507724A (zh) 2020-11-08 2023-07-28 波涛生命科学有限公司 寡核苷酸组合物及其方法
EP4404942A4 (en) 2021-09-26 2026-06-17 Wave Life Sciences Ltd Compositions for the Editing of Transcripts MECP2 and Related Processes
CA3232070A1 (en) 2021-09-26 2023-03-30 Prashant MONIAN Oligonucleotide compositions and methods thereof
AU2021471586A1 (en) 2021-10-27 2024-05-09 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP4422645A4 (en) 2021-10-27 2025-12-03 Wave Life Sciences Ltd OLIGONUCLEOTID COMPOSITIONS AND THEIR METHODS OF USE
EP4476202A4 (en) 2022-02-11 2026-06-10 Wave Life Sciences Ltd STEREOSELECTIVE TECHNOLOGIES FOR CHIRICAL COMPOUNDS
US20250197857A1 (en) 2022-03-02 2025-06-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods thereof for exon skipping
EP4507700A2 (en) 2022-04-15 2025-02-19 Wave Life Sciences Ltd. Oligonucleotide compositions and methods relating thereto
CN119452084A (zh) 2022-05-12 2025-02-14 波涛生命科学有限公司 寡核苷酸组合物及其方法
EP4569115A4 (en) 2022-08-11 2026-07-15 Wave Life Sciences Ltd OLIGONUCLEOTID COMPOSITIONS AND ASSOCIATED PROCESSES

Also Published As

Publication number Publication date
US12435105B2 (en) 2025-10-07
SG11202000276YA (en) 2020-04-29
US20260008806A1 (en) 2026-01-08
US20200231620A1 (en) 2020-07-23
US20230348524A1 (en) 2023-11-02
AU2018333065B2 (en) 2024-04-18
CA3072110A1 (en) 2019-03-21
CN111108096A (zh) 2020-05-05
JP2024105256A (ja) 2024-08-06
WO2019055951A1 (en) 2019-03-21
EP3684755A4 (en) 2022-03-02
KR20200052369A (ko) 2020-05-14
JP2021500311A (ja) 2021-01-07
JP7472018B2 (ja) 2024-04-22
EP3684755A1 (en) 2020-07-29
AU2018333065A1 (en) 2020-01-30
AU2024204904A1 (en) 2024-08-01
US11608355B2 (en) 2023-03-21

Similar Documents

Publication Publication Date Title
JP7472018B2 (ja) オリゴヌクレオチド調製のための技術
AU2026202225A1 (en) Technologies useful for oligonucleotide preparation
US12428442B2 (en) Compounds, compositions and methods for synthesis
JP7296882B2 (ja) ホスホラミダイト及びオリゴヌクレオチド合成のための組成物及び方法
CN118660876A (zh) 手性化合物的立体选择性技术
AU2019252680A1 (en) Oligonucleotide compositions and methods of use thereof
TW202237847A (zh) 聚-𠰌啉代寡核苷酸缺口體
TW202237848A (zh) 靶向tau之寡核苷酸缺口體
HK40019008A (en) Technologies for oligonucleotide preparation
BR112021018492B1 (pt) Método para preparar um oligonucleotídeo e oligonucleotídeo
Matulic-Adamic et al. Synthesis and Incorporation of 5 ″-Amino-and 5′-Mercapto-5′-Deoxy-2′-O-Methyl Nucleosides Into Hammerhead Ribozymes
FR2612930A1 (fr) Sondes oligonucleotidiques a
JP2005255528A (ja) 新規炭酸エステル誘導体及びそれらを利用する核酸合成法

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000